The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
about
Targeting folate receptor alpha for cancer treatmentProfile of farletuzumab and its potential in the treatment of solid tumorsImmunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.Folate receptor-α (FOLR1) expression and function in triple negative tumorsA phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors.Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.Targeted agents and combinations in ovarian cancer: where are we now?Myeloid differentiation factor 88 promotes cisplatin chemoresistance in ovarian cancer.Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagementIdentification of a Folate Receptor-Targeted Near-Infrared Molecular Contrast Agent to Localize Pulmonary Adenocarcinomas.FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.
P2860
Q26744215-633BF8DF-2AE7-4960-B4A0-15C1903ABAF5Q26750431-BC671A7C-839F-4206-AC87-4C58B1A988ABQ34979610-0A7A66FA-4D0B-4EFF-9144-DB269617B10DQ35225064-B90E1331-E05A-418C-8058-91F748F07FF6Q35288804-D8C2B923-5C62-4816-93F5-503A13132833Q36508941-1AA4D1BA-94A3-4BC5-92E3-6313D2EA34B3Q38309549-6901A332-E97D-4FCA-AA6D-A2BEE5379478Q38524502-595DD266-730F-4097-A23C-572A4B41C1C1Q38760610-16DC31A4-BFCC-4702-A169-9069137F5F7CQ38948577-C4E77D84-F733-45EA-8457-CE4FC34FF503Q41592587-7EB6DAA8-BA6D-4B80-9773-D38ECE7F03C9Q47308208-F60749B9-5B35-44C9-9B0D-8554DB9FFD08Q49869601-DEFFB631-EE19-4963-9417-1502EABE887BQ55008640-89AF2F5E-CB0D-4F16-BBB7-6A43E5ABDA8A
P2860
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The antitumor activity of the ...... pendent cellular cytotoxicity.
@en
The antitumor activity of the ...... pendent cellular cytotoxicity.
@nl
type
label
The antitumor activity of the ...... pendent cellular cytotoxicity.
@en
The antitumor activity of the ...... pendent cellular cytotoxicity.
@nl
prefLabel
The antitumor activity of the ...... pendent cellular cytotoxicity.
@en
The antitumor activity of the ...... pendent cellular cytotoxicity.
@nl
P2093
P2860
P921
P356
P1476
The antitumor activity of the ...... ependent cellular cytotoxicity
@en
P2093
Bryon P Martinez
Candice L M Krauthauser
Christopher J Maddage
Earl F Albone
J Bradford Kline
JianMin Lin
Katherine A Rybinski
Luigi Grasso
Matthew T Goserud
Nicholas C Nicolaides
P2860
P304
P356
10.4161/CBT.26106
P577
2013-08-28T00:00:00Z